Axial spondyloarthritis

The Lancet

Volumn 390, Issue 10089, 2017, Pages 73-84

  Sieper, Joachim ^a   Poddubnyy, Denis ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B27 ANTIGEN; INTERLEUKIN 17; NONSTEROID ANTIINFLAMMATORY AGENT; SECUKINUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

BONE INJURY; BONE RADIOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPONDYLARTHRITIS; TREATMENT OUTCOME; BACK PAIN; CLASSIFICATION; EARLY DIAGNOSIS; PATHOPHYSIOLOGY; PROCEDURES; SPONDYLITIS, ANKYLOSING;

BACK PAIN; EARLY DIAGNOSIS; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; SPONDYLITIS, ANKYLOSING;

EID: 85009895685     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31591-4     Document Type: Review

References (144)

1. Rudwaleit, M, van der Heijde, D, Landewe, R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68 (2009), 777–783.
2. van der Linden, S, Valkenburg, HA, Cats, A, Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (1984), 361–368.
3. Dougados, M, van der Linden, S, Juhlin, R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991), 1218–1227.
4. Amor, B, Dougados, M, Mijiyawa, M, Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57 (1990), 85–89.
5. Deodhar, A, Strand, V, Kay, J, Braun, J, The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 75 (2016), 791–794.
6. Deodhar, A, Reveille, JD, van den Bosch, F, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumat 66 (2014), 2649–2656.
7. Calin, A, Porta, J, Fries, JF, Schurman, DJ, Clinical history as a screening test for ankylosing spondylitis. JAMA 237 (1977), 2613–2614.
8. Rudwaleit, M, Metter, A, Listing, J, Sieper, J, Braun, J, Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54 (2006), 569–578.
9. Sieper, J, van der Heijde, D, Landewe, R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68 (2009), 784–788.
10. Sieper, J, Rudwaleit, M, Baraliakos, X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:suppl 2 (2009), ii1–i44.
11. Ramiro, S, van Tubergen, A, Stolwijk, C, van der Heijde, D, Royston, P, Landewe, R, Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study. Ann Rheum Dis 74 (2015), 1218–1224.
12. Garrett, S, Jenkinson, T, Kennedy, LG, Whitelock, H, Gaisford, P, Calin, A, A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21 (1994), 2286–2291.
13. Machado, P, Landewe, R, Lie, E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70 (2010), 47–53.
14. Vander Cruyssen, B, Ribbens, C, Boonen, A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 66 (2007), 1072–1077.
15. Rudwaleit, M, Haibel, H, Baraliakos, X, et al. The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. Arthritis Rheum 60 (2009), 717–727.
16. Dougados, M, Etcheto, A, Molto, A, et al. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. Joint Bone Spine 82 (2015), 345–351.
17. Jaakkola, E, Herzberg, I, Laiho, K, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 65 (2006), 775–780.
18. van Tubergen, A, The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol 11 (2015), 110–118.
19. Stolwijk, C, van Onna, M, Boonen, A, van Tubergen, A, The global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care Res (Hoboken) 68 (2016), 1320–1331.
20. Khan, MA, Kushner, I, Braun, WE, Letter: Low incidence of HLA-B27 in American Blacks with spondyloarthropathies. Lancet, 1, 1976, 483.
21. Reveille, JD, Witter, JP, Weisman, MH, Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken) 64 (2012), 905–910.
22. Bakland, G, Alsing, R, Singh, K, Nossent, JC, Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27. Arthritis Care Res (Hoboken) 65 (2013), 448–453.
23. Costantino, F, Talpin, A, Said-Nahal, R, et al. Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis 74 (2015), 689–693.
24. Brown, MA, Kennedy, LG, MacGregor, AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 40 (1997), 1823–1828.
25. Ellinghaus, D, Jostins, L, Spain, SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 48 (2016), 510–518.
26. International Genetics of Ankylosing Spondylitis C, Cortes, A, Hadler, J, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45 (2013), 730–738.
27. Evans, DM, Spencer, CC, Pointon, JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43 (2011), 761–767.
28. Carter, JD, Gerard, HC, Espinoza, LR, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 60 (2009), 1311–1316.
29. Van Praet, L, Jans, L, Carron, P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis 73 (2014), 1186–1189.
30. Nagalingam, NA, Lynch, SV, Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 18 (2012), 968–984.
31. Asquith, M, Elewaut, D, Lin, P, Rosenbaum, JT, The role of the gut and microbes in the pathogenesis of spondyloarthritis. Best Pract Res Clin Rheumatol 28 (2014), 687–702.
32. Costello, ME, Ciccia, F, Willner, D, et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol, 2014, 10.1002/art.38967 published online Nov 21.
33. Baraliakos, X, Baerlecken, N, Witte, T, Heldmann, F, Braun, J, High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 73 (2014), 1079–1082.
34. Baerlecken, NT, Nothdorft, S, Stummvoll, GH, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 73 (2014), 1211–1214.
35. Appel, H, Maier, R, Wu, P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther, 13, 2011, R95.
36. Gracey, E, Qaiyum, Z, Almaghlouth, I, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-208902 published online May 10.
37. Noordenbos, T, Blijdorp, I, Chen, S, et al. Human mast cells capture, store, and release bioactive, exogenous IL-17A. J Leukoc Biol 100 (2016), 453–462.
38. Miossec, P, Kolls, JK, Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11 (2012), 763–776.
39. Uluckan, O, Jimenez, M, Karbach, S, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med, 8, 2016, 330ra37.
40. Sherlock, JP, Joyce-Shaikh, B, Turner, SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18 (2012), 1069–1076.
41. Appel, H, Maier, R, Bleil, J, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 65 (2013), 1522–1529.
42. Jacques, P, Lambrecht, S, Verheugen, E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 73 (2014), 437–445.
43. Lories, R, The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol 7 (2011), 700–707.
44. Bleil, J, Maier, R, Hempfing, A, et al. Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis. Arthritis Rheumatol 66 (2014), 1745–1754.
45. Ruiz-Heiland, G, Horn, A, Zerr, P, et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 71 (2012), 400–407.
46. Appel, H, Ruiz-Heiland, G, Listing, J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60 (2009), 3257–3262.
47. Heiland, GR, Appel, H, Poddubnyy, D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71 (2012), 572–574.
48. Tsui, FW, Tsui, HW, Las Heras, F, Pritzker, KP, Inman, RD, Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 73 (2014), 1873–1879.
49. Poddubnyy, D, Haibel, H, Listing, J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64 (2012), 1388–1398.
50. Maksymowych, WP, Landewe, R, Conner-Spady, B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56 (2007), 1846–1853.
51. Poddubnyy, D, Conrad, K, Haibel, H, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 73 (2014), 2137–2143.
52. Turina, MC, Sieper, J, Yeremenko, N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 73 (2014), 1746–1748.
53. Syrbe, U, Callhoff, J, Conrad, K, et al. Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheumat 67 (2015), 678–685.
54. Maksymowych, WP, Morency, N, Conner-Spady, B, Lambert, RG, Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 72 (2013), 23–28.
55. Baraliakos, X, Heldmann, F, Callhoff, J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 73 (2014), 1819–1825.
56. Bleil, J, Maier, R, Hempfing, A, Sieper, J, Appel, H, Syrbe, U, Granulation tissue eroding the subchondral bone also promotes new bone formation in ankylosing spondylitis. Arthritis Rheumat 68 (2016), 2456–2465.
57. Machado, PM, Baraliakos, X, van der Heijde, D, Braun, J, Landewe, R, MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis 75 (2016), 1486–1493.
58. Rudwaleit, M, van der Heijde, D, Landewe, R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70 (2011), 25–31.
59. Robinson, PC, Wordsworth, BP, Reveille, JD, Brown, MA, Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis 72 (2013), 162–164.
60. Sieper, J, van der Heijde, D, Review: nonradiographic axial spondyloarthritis: new definition of an old disease?. Arthritis Rheum 65 (2013), 543–551.
61. van der Linden, S, Akkoc, N, Brown, MA, Robinson, PC, Khan, MA, The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward. Curr Rheumatol Rep, 17, 2015, 62.
62. Sepriano, A, Landewe, R, van der Heijde, D, et al. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Ann Rheum Dis 75 (2016), 1034–1042.
63. van den Berg, R, de Hooge, M, van Gaalen, F, Reijnierse, M, Huizinga, T, van der Heijde, D, Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology (Oxford) 52 (2013), 1492–1499.
64. Molto, A, Paternotte, S, Comet, D, et al. Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. Arthritis Care Res (Hoboken) 65 (2013), 1472–1481.
65. Tomero, E, Mulero, J, de Miguel, E, et al. Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. Rheumatology (Oxford) 53 (2014), 353–360.
66. Strand, V, Rao, SA, Shillington, AC, Cifaldi, MA, McGuire, M, Ruderman, EM, Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (Hoboken) 65 (2013), 1299–1306.
67. Rudwaleit, M, Khan, MA, Sieper, J, The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 52 (2005), 1000–1008.
68. Aggarwal, R, Ringold, S, Khanna, D, et al. Distinctions between diagnostic and classification criteria?. Arthritis Care Res (Hoboken) 67 (2015), 891–897.
69. van den Berg, R, de Hooge, M, Rudwaleit, M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis 72 (2013), 1646–1653.
70. Mandl, P, Navarro-Compan, V, Terslev, L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 74 (2015), 1327–1339.
71. Poddubnyy, D, Brandt, H, Vahldiek, J, et al. The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. Ann Rheum Dis 71 (2012), 1998–2001.
72. Poddubnyy, D, Rudwaleit, M, Haibel, H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 70 (2011), 1369–1374.
73. van Tubergen, A, Heuft-Dorenbosch, L, Schulpen, G, et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality?. Ann Rheum Dis 62 (2003), 519–525.
74. van den Berg, R, Lenczner, G, Feydy, A, et al. Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs. Results from the DESIR cohort. Arthritis Rheumatol 66 (2014), 2403–2411.
75. Krohn, M, Braum, LS, Sieper, J, et al. Erosions and fatty lesions of sacroiliac joints in patients with axial spondyloarthritis: evaluation of different MRI techniques and two scoring methods. J Rheumatol 41 (2014), 473–480.
76. Lambert, RG, Bakker, PA, van der Heijde, D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 75 (2016), 1958–1963.
77. Weber, U, Ostergaard, M, Lambert, RG, et al. Candidate lesion-based criteria for defining a positive sacroiliac joint MRI in two cohorts of patients with axial spondyloarthritis. Ann Rheum Dis 74 (2015), 1976–1982.
78. Weber, U, Zubler, V, Zhao, Z, et al. Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?. Ann Rheum Dis 74 (2015), 985–992.
79. Hermann, KG, Baraliakos, X, van der Heijde, DM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis 71 (2012), 1278–1288.
80. Weber, U, Zhao, Z, Rufibach, K, et al. Diagnostic utility of candidate definitions for demonstrating axial spondyloarthritis on magnetic resonance imaging of the spine. Arthritis Rheumatol 67 (2015), 924–933.
81. Song, IH, Carrasco-Fernandez, J, Rudwaleit, M, Sieper, J, The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 67 (2008), 1535–1540.
82. Poddubnyy, D, Vahldiek, J, Spiller, I, et al. Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 38 (2011), 2452–2460.
83. Sieper, J, Srinivasan, S, Zamani, O, et al. Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 72 (2013), 1621–1627.
84. Rudwaleit, M, Sieper, J, Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol 8 (2012), 262–268.
85. van Hoeven, L, Vergouwe, Y, de Buck, PD, Luime, JJ, Hazes, JM, Weel, AE, External validation of a referral rule for axial spondyloarthritis in primary care patients with chronic low back pain. PLoS One, 10, 2015, e0131963.
86. Deodhar, A, Mittal, M, Reilly, P, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol 35 (2016), 1769–1776.
87. Poddubnyy, D, van Tubergen, A, Landewe, R, Sieper, J, van der Heijde, D, for the Assessment of Spondylo Arthritis international group. Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis 74 (2015), 1483–1487.
88. Poddubnyy, D, van Tubergen, A, Landewe, R, Sieper, J, van der Heijde, D, Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: ‘Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?’ by van Hoeven et al. Ann Rheum Dis, 74, 2015, e69.
89. Van Heijde, D, Ramiro, S, Landewé R, et al. 2016 update of the ASAS/EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis, 2017, 10.1136/annrheumdis-2016-210770 published online Jan 13.
90. Ward, MM, Deodhar, A, Akl, EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 68 (2016), 151–166.
91. Smolen, JS, Braun, J, Dougados, M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73 (2014), 6–16.
92. Song, IH, Poddubnyy, DA, Rudwaleit, M, Sieper, J, Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58 (2008), 929–938.
93. Sieper, J, Lenaerts, J, Wollenhaupt, J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73 (2014), 101–107.
94. Sieper, J, Klopsch, T, Richter, M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67 (2008), 323–329.
95. van der Heijde, D, Baraf, HS, Ramos-Remus, C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52 (2005), 1205–1215.
96. Kroon, FP, van der Burg, LR, Ramiro, S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev, 7, 2015 CD010952.
97. Wang, R, Dasgupta, A, Ward, MM, Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis 75 (2016), 1152–1160.
98. Bakland, G, Gran, JT, Nossent, JC, Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70 (2011), 1921–1925.
99. Haroon, NN, Paterson, JM, Li, P, Inman, RD, Haroon, N, Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163 (2015), 409–416.
100. Coxib and traditional NSAID Trialists' Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
101. Lie, E, Kristensen, LE, Forsblad-d'Elia, H, et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 74 (2015), 970–978.
102. Nissen, MJ, Ciurea, A, Bernhard, J, et al. The effect of comedication with a csDMARD on drug retention and clinical effectiveness of anti-TNF therapy in patients with axial spondyloarthritis. Arthritis Rheumat 68 (2016), 2140–2150.
103. Breban, M, Ravaud, P, Claudepierre, P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58 (2008), 88–97.
104. Heiberg, MS, Koldingsnes, W, Mikkelsen, K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59 (2008), 234–240.
105. Sepriano, A, Ramiro, S, van der Heijde, D, et al. Effect of comedication with conventional synthetic DMARDs on TNF inhibitors-retention in patients with spondyloarthritis: A prospective cohort. Arthritis Rheumat 68 (2016), 2671–2679.
106. Haibel, H, Heldmann, F, Braun, J, Listing, J, Kupper, H, Sieper, J, Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum 65 (2013), 2211–2213.
107. Braun, J, Brandt, J, Listing, J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002), 1187–1193.
108. Davis, JC Jr, Van Der Heijde, D, Braun, J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48 (2003), 3230–3236.
109. van der Heijde, D, Kivitz, A, Schiff, MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 (2006), 2136–2146.
110. Inman, RD, Davis, JC Jr, Heijde, D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58 (2008), 3402–3412.
111. Landewe, R, Braun, J, Deodhar, A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73 (2014), 39–47.
112. Davis, JC, van der Heijde, DM, Braun, J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64 (2005), 1557–1562.
113. van der Heijde, D, Dijkmans, B, Geusens, P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52 (2005), 582–591.
114. Baeten, D, Sieper, J, Braun, J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373 (2015), 2534–2548.
115. Sieper, J, van der Heijde, D, Dougados, M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72 (2013), 815–822.
116. Dougados, M, van der Heijde, D, Sieper, J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumat 66 (2014), 2091–2102.
117. Sieper, J, van der Heijde, D, Dougados, M, et al. a randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumat 67 (2015), 2702–2712.
118. Brown, MD, Bird, PA, Robinson, PC, et al. Baseline MRI/CRP as predictors of response to etanercept in the management of patients with non-radiographic axial spondyloarthritis. Ann Rheum Dis, 74(suppl 2), 2015, 752.
119. Rudwaleit, M, Schwarzlose, S, Hilgert, ES, Listing, J, Braun, J, Sieper, J, MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67 (2008), 1276–1281.
120. Sieper, J, Poddubnyy, D, New evidence on the management of spondyloarthritis. Nat Rev Rheumatol 12 (2016), 282–295.
121. Baraliakos, X, Listing, J, Brandt, J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7 (2005), R439–R444.
122. Song, IH, Althoff, CE, Haibel, H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 71 (2012), 1212–1215.
123. Haibel, H, Heldmann, F, Listing, J, Kupper, H, Braun, J, Sieper, J, Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. Arthritis Rheum 65 (2013), 2211–2213.
124. Sieper, J, Lenaerts, J, Wollenhaupt, J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73 (2014), 108–113.
125. Cantini, F, Niccoli, L, Cassara, E, Kaloudi, O, Nannini, C, Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biologics 7 (2013), 1–6.
126. Yates, M, Hamilton, LE, Elender, F, et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? a randomized control trial. J Rheumatol 42 (2015), 1177–1185.
127. Song, IH, Heldmann, F, Rudwaleit, M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62 (2010), 1290–1297.
128. Song, IH, Heldmann, F, Rudwaleit, M, et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 72 (2013), 305–306.
129. Sieper, J, Porter-Brown, B, Thompson, L, Harari, O, Dougados, M, Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73 (2014), 95–100.
130. Sieper, J, Braun, J, Kay, J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74 (2015), 1051–1057.
131. Sieper, J, Deodhar, A, Marzo-Ortega, H, et al. Secukinumab Efficacy in Anti–TNF-naïve and Anti–TNF-experienced Subjects with Active Ankylosing Spondylitis: Results from the MEASURE 2 Study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2016-210023 published online Aug 31.
132. Braun, J, Baraliakos, X, Deodhar, A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2016-209730 published online Dec 13.
133. Poddubnyy, D, Hermann, KG, Callhoff, J, Listing, J, Sieper, J, Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73 (2014), 817–823.
134. van der Heijde D, Deodhar A, Wei J, et al. Tofacitinib in patients with ankylosing spondylitis: A phase 2, 16 week, randomized, placebo-controlled, dose-ranging study. American College of Rheumatology conference 2015; San Francisco, CA; Nov 6–11, 2015; 5L.
135. Pathan, E, Abraham, S, Van Rossen, E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 72 (2013), 1475–1480.
136. US National Library of Science. https://clinicaltrials.gov/ct2/show/results/NCT01583374?sect=X3401256%23wrapper, 2016 (accessed Dec 19, 2016).
137. van der Heijde, D, Landewe, R, Baraliakos, X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58 (2008), 3063–3070.
138. Braun, J, Baraliakos, X, Hermann, KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 73 (2014), 1107–1113.
139. Haroon, N, Inman, RD, Learch, TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65 (2013), 2645–2654.
140. Baraliakos, X, Haibel, H, Listing, J, Sieper, J, Braun, J, Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73 (2014), 710–715.
141. Wanders, A, Heijde, D, Landewe, R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52 (2005), 1756–1765.
142. Boersma, JW, Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 5 (1976), 60–64.
143. Poddubnyy, D, Rudwaleit, M, Haibel, H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71 (2012), 1616–1622.
144. Sieper, J, Listing, J, Poddubnyy, D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75 (2016), 1438–1443.